FDA accepts z-rostudirsen BLA with Priority Review; PDUFA January 21, 2027

Dyne Therapeutics/Z-rostudirsen (DYNE-251)

FDA accepted z-rostudirsen BLA with Priority Review, setting PDUFA target date January 21, 2027. Dyne expects potential Q1 2027 U.S. launch if approved as anticipated.